Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced new cost-effectiveness data for VOQUEZNA® (vonoprazan), alongside additional clinical and real-world data, presented at the American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting, being held October 9-14 in Nashville, Tennessee. A new predictive cost-effectiveness analysis projected VOQUEZNA to provide meaningful economic value and be cost-effective compared with proton pump inhibitors (PPIs) for the healing and maintenance of Erosive Esophagitis or Erosive Gastroesophageal Reflux Disease (GERD) over patients’ lifetimes, with potential cost savings at net price based on clinical healing and maintenance of healing data and fewer anticipated downstream complications.
Covered in this story
What has happened since
- Phathom Pharmaceuticals Inc is down 1.7% since this was published, 10 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $PHAT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Phathom Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.